You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
國內將大規模開展核酸和抗體檢測,醫藥多個板塊走強
格隆匯 04-23 10:17

4月22日,中央應對新冠肺炎疫情工作領導小組召開會議。會議指出,做到“四早”首要是早發現。做好常態化防控要加快提升檢測能力,大規模開展核酸和抗體檢測。要加快提升檢測技術,抓緊增加更簡便、更高效準確的檢測設備生產,廣泛配備到醫院、口岸等急需方面,擴大商業化應用,做到對重點人羣應檢盡檢,對復工復產中人員聚集的單位、場所優先做到願檢盡檢。

而在此之前,包括北京、瀋陽在內的多地已經下發通知,擴大核酸檢測範圍,加強重點人羣核酸檢測。

受消息的刺激,4月23日,A股市場的生物製品、生物疫苗、流感、基因測序等醫藥板塊漲幅排在市場前列。

(圖片來源:同花順)

上述一些板塊內更有多隻相關概念股錄得漲停。例如,基因測序板塊內的昌紅科技、邁克生物、達安基因、海利生物均在今日強勢漲停,華大基因、迪安診斷、美康生物等個股也都大漲。

(圖片來源:同花順)

據悉,昌紅科技(300151.SZ)於2月3日在互動平台上表示,全資子公司深圳市柏明勝醫療器械有限公司生產的體外診斷試劑耗材及檢測試劑盒均為本次抗擊新型冠狀病毒疫情的配套產品。

達安基因(002030.SZ)此前同樣在互動平台上表示,公司已向武漢等地的幾百家各級疾控中心和醫院提供新型冠狀病毒檢測試劑盒,用於開展臨牀疾病預防監控。

而在4月21日,阿里巴巴旗下阿里健康宣佈,聯合美年健康和迪安健檢天貓旗艦店,首期在10個城市推出在線預約新冠核酸檢測服務,本週內將陸續覆蓋38座城市。

迪安診斷集團客服中心負責人則於22日表示,諮詢的增量超出預期,“昨晚接待時間一直延到凌晨後”,客服人均接待諮詢超300人次。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account